Patent ductus arteriosus therapy: Impact on neonatal and 18-month outcome

Pediatrics

Volumn 123, Issue 2, 2009, Pages 674-681

  Madan, Juliette C ^a   Kendrick, Douglas ^b   Hagadorn, James I ^a,c   Frantz III, Ivan D ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b RTI INTERNATIONAL   (United States)

^c UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Bronchopulmonary dysplasia; Necrotizing enterocolitis; Neurodevelopmental impairment; Patent ductus arteriosus; Therapyductus arteriosus

Indexed keywords

INDOMETACIN;

ARTICLE; BIRTH WEIGHT; CARDIOVASCULAR RISK; CONTROLLED STUDY; EXTREMELY LOW BIRTH WEIGHT; FEMALE; GESTATIONAL AGE; HUMAN; INFANT; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; NECROTIZING ENTEROCOLITIS; NEUROLOGIC DISEASE; NEWBORN; PATENT DUCTUS ARTERIOSUS; PRIORITY JOURNAL; PROPHYLAXIS; SURGICAL TECHNIQUE; TREATMENT OUTCOME; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDY; TIME;

DUCTUS ARTERIOSUS, PATENT; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 61549099321     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2007-2781     Document Type: Article

References (39)

1. Fanaroff AA, Stoll BJ, Wright LL, et al. Trends in neonatal morbidity and mortality for very low birth weight infants. Am J Obstet Gynecol. 2007;196(2):147.e1-147.e8
2. Lee SK, McMillan DD, Ohlsson A, et al. Variations in practice and outcomes in the Canadian NICU network 1996-1997. Pediatrics. 2000;106(5):1070-1079
3. Itabashi K, Ohno T, Nishida, H. Indomethacin responsiveness of patent ductus arteriosus and renal abnormalities in preterm infants treated with indomethacin. J Pediatr. 2003;143(2):203-207
4. Gersony WM, Peckham GJ, Ellison RC, Miettinen OS, Nadas AS. Effects of indomethacin in premature infants with PDA: results of a national collaborative study. J Pediatr. 1983;102(6):895-906
5. Grosfeld JL, Chaet M, Molinari F, Engle W, Engum SA, West KW. Increased risk of NEC in premature infants with PDA treated with indomethacin. Ann Surg. 1996;224(3):350-355
6. Cotton RB, Stahlman MT, Kovar I, Catterton WZ. Medical management of small preterm infants with symptomatic patent ductus arteriosus. J Pediatr. 1979;92(3):467-473
7. Satur CR, Walker DR, Dickinson DF. Day case surgical closure of PDA in preterm infants: a 10 year review. Arch Dis Child. 1991;66(4):477-480
8. Narayanan M, Cooper B, Weiss H, Clyman RI. Prophylactic indomethacin: factors determining permanent ductus arteriosus closure. J Pediatr. 2000;136(3):330-337
9. Little DC, Pratt TC, Blalock SE, Krauss DR, Cooney DR, Custer MD. PDA in micropreemies and full term infants: the relative merits of surgical closure versus indomethacin treatment. J Pe- diatr Surg. 2003;38(3):492-496
10. Quinn D, Cooper B, Clyman RI. Factors associated with permanent closure of the ductus arteriosus: a role for prolonged indomethacin therapy. Pediatrics. 2002;110(1). Available at: www.pediatrics.org/cgi/content/ full/110/1/e10
11. Sperandio M, Beedgen B, Feneberg R, et al. Effectiveness and side effects of an escalating, stepwise approach to indometha- cin treatment for symptomatic PDA in premature infants below 33 weeks of gestation. Pediatrics. 2005;116(6):1361-1366
12. Koch J, Hensley G, Roy L, Brown S, Ramaciotti Cl, Rosenfeld C. Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less. Pediatrics. 2006;117(4):1113-1121
13. Jaillard S, Larrue B, Rakza T, Magnenant E, Warembourg H, Storme L. Consequences of delayed surgical closure of PDA in very premature infants. Ann Thorac Surg. 2006;81(1):231-234
14. Madan J, Fiascone J, Griffith J, Balasubramanian V, Hagadorn J. Predictors of successful ductal closure, necrotizing enteroco- litis, and focal intestinal perforation in very low birth weight infants treated with indomethacin or surgical ligation for patent ductus arteriosus. Neonatology. 2008;94(1):45-51
15. Keller RL, Clyman RI. Persistent Doppler flow predicts lack of response to multiple courses of indomethacin in premature infants with recurrent patent ductus arteriosus. Pediatrics. 2003;112(3 pt 1):583-587
16. Mavroudis C, Cook LN, Fleischaker JW, et al. Management of PDA in preterm infants; indomethacin versus surgical closure. Ann Thorac Surg. 1983;36(5):561-566
17. Malviya M, Ohlsson A, Shah S. Surgical versus medical therapy with cyclooxygenase inhibitors for symptomatic PDA in pre- term infants. Cochrane Database Syst Rev. 2003;(3):CD003951
18. O'Donovan DJ, Baetiong A, Adams K, et al. NEC and GI complications after indomethacin therapy and surgical closure in premature infants with PDA. J Perinatol. 2003;23(4):286-290
19. Lee LC, Tillett A, Tulloh R, Yates R, Kelsall W. Outcome following PDA surgical closure in premature infants: a retrospective cohort analysis. BMC Pediatr. 2006;6:15
20. Laughon M, Bose C, Clark R. Treatment strategies to prevent or close a PDA in preterm infants and outcomes. J Perinatol. 2007;27(3):164-170
21. Chorne N, Leonard C, Piecuch R, Clyman RI. PDA and its treatment as risk factors for neonatal and neurodevelopmental morbidity. Pediatrics. 2007;119(6):1165-1174
22. Kabra NS, Schmidt B, Roberts RS, et al. Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms. J Pediatr. 2007;150(3):229-234, 29
23. Vanhaesebrouck S, Zonnenberg I, Vandervoort P, Bruneel E, Van Hoestenberghe MR, Theyskens C. Conservative treatment for PDA in the preterm. Arch Dis Child Fetal Neonatal Ed. 2007; 92(4):F244-F247
24. Bose CL, Laughon MM. PDA: lack of evidence for common treatments. Arch Dis Child Fetal Neonatal Ed. 2007;92(6):F498 -F502
25. Fowlie PW, Davis PG. Prophylactic indomethacin for preterm infants: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2003;88(6):F464-F466
26. Schmidt B, Davis P, Moddemann D, et al. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight- infants. N Engl J Med. 2001;344(26):1966-1972
27. Ment LR, Vohr B, Oh W, et al. Neurodevelopmental outcome at 36 months' corrected age of preterm infants in the Multi- center Indomethacin Intraventricular Hemorrhage Prevention Trial. Pediatrics. 1996;98(4 pt 1):714-718
28. Bell MJ, Ternberg JL, Keating JP, Marshall R, Barton L, Broth- erton T. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg. 1978;187(1):1-7
29. Clyman RI, Chorne N. Patent ductus arteriosus: evidence for and against treatment. J Pediatr. 2007;150(3):216 -219
30. Doyle LW; Victorian Infant Collaborative Study Group. Outcome at 5 years of age of children 23 to 27. weeks' gestation: refining the prognosis. Pediatrics. 2001;108(1):134-141
31. Gonzales A, Sosenko IR, Chandar J, Hummler H, Claure N, Bancalari E. Influence of infection on PDA and chronic lung disease in premature infants weighing 1000 grams or less. J Pediatr. 1996;12:470-478
32. Merritt TA, Harris JP, Roghmann K, et al. Early closure of PDA in VLBW infants: a controlled trial. J Pediatr. 1981;99(2): 281-286
33. Rojas MA, Gonzales A, Bancalari E, Claure N, Poole C, Silva- Neto G. Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease. J Pediatr. 1995;126(4):605-610
34. Zanardo V, Trevisanuto D, Dani C, et al. "Silent" PDA and BPD in VLBW infants. J Perinat Med. 1995;23(6):493-499
35. Watterberg K. Anti-inflammatory therapy in the NICU: present and future. Semin Fetal Neonatal Med. 2006;11(5):378-384
36. Laughon MM, Simmons MA, Bose CL. Patency of the ductus arteriosus in the premature infant: is it pathologic? Should it be treated? Curr Opin Pediatr. 2004;16(2):146-151
37. Ment LR, Oh W, Ehrenkranz RA, et al. Low-dose indomethacin and prevention of intraventricular hemorrhage: a multi- center randomized trial. Pediatrics. 1994;93(4):542-550
38. Cordero L, Nankervis CA, Delooze D, Giannone PJ. Indometh- acin prophylaxis or expectant treatment of patent ductus arte- riosus in extremely low birth weight infants? JPerinatol. 2007; 27(3):158-163
39. Ment LR, Vohr B, Allan W, et al. Outcome of children in the indomethacin intraventricular hemorrhage prevention trial. Pediatrics. 2000;105(3 pt 1):485-491